OncLive TV

Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

James H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.

Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Stephanie J. Lee, MD, MPH, discusses the results of the phase 3 REACH3 trial in chronic graft-vs-host disease.

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

Charles Powell, MD, MBA, discusses managing fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Natasha Garg, DO, discusses selecting between antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Bhuvaneswari Ramaswamy, MD, discusses the potential utility of CDK4/6 inhibitors in the adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer.

Bruna Pellini, MD, discusses the challenges of using topotecan as a comparator arm for second-line clinical trials in extensive-stage small cell lung cancer.

Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.

James H. Doroshow, MD, discusses the importance of modernizing clinical trials in the post–COVID-19 era.

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

Elyse Lower, MD, discusses the impact of tucatinib on the treatment of patients with HER2-positive breast cancer.